Viking Therapeutics(US:VKTX) Prnewswireยท2024-10-31 20:05Company Participation in Investor Conferences - Viking Therapeutics will participate in several upcoming investor conferences, including the Truist Healthcare Conference on November 7, 2024, the UBS Global Healthcare Conference from November 11-14, 2024, the Stifel 2024 Healthcare Conference on November 18-19, 2024, and the Jefferies London Healthcare Conference from November 19-21, 2024 [1] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with three compounds currently in clinical trials [2] - The company's lead compound, VK2735, is a dual agonist for GLP-1 and GIP receptors, showing positive safety and clinical benefit in Phase 1 and Phase 2 trials for metabolic disorders [2] - VK2809, another compound, is a selective thyroid hormone receptor beta agonist that has met primary and secondary endpoints in a Phase 2b study for NASH and fibrosis, and has shown significant reductions in LDL-C and liver fat in a Phase 2a trial for NAFLD [2] - The company is also developing VK0214 for X-ALD, which demonstrated safety and significant reductions in VLCFAs in a Phase 1b trial [2]